Compare CSPI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | AGEN |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.1M | 126.2M |
| IPO Year | 1994 | 1999 |
| Metric | CSPI | AGEN |
|---|---|---|
| Price | $8.44 | $3.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 26.5K | ★ 387.3K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | 0.01 | ★ 0.37 |
| Revenue | ★ $58,730,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | $862.00 | ★ $9.14 |
| Revenue Growth | 6.36 | ★ 89.95 |
| 52 Week Low | $8.04 | $1.38 |
| 52 Week High | $17.94 | $7.34 |
| Indicator | CSPI | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 53.97 |
| Support Level | $8.04 | $2.90 |
| Resistance Level | $12.89 | $3.38 |
| Average True Range (ATR) | 0.53 | 0.18 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 20.36 | 60.17 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).